



CS/NSE&BSE/UFR/2017-18
November 11, 2017

To
The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (E), Mumbai – 400 051

To
The General Manager
Department of Corporate Services
BSE Limited
25th Floor, P. J. Towers,
Dalal Street, Mumbai - 400 001

Stock Code: SUVEN–EQ

Stock Code: 530239

Dear Sir/Madam,

Sub: Notification of Un-audited Financial Results for the quarter and half-year ended 30th September, 2017

.....

With reference to the above subject, pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board of Directors of the company, at its meeting held today i.e. 11th November, 2017, has taken on record the Standalone Un-audited Financial Results of the Company under Ind AS for the quarter and half-year ended 30th September, 2017.

We are enclosing herewith the **Un-audited Financial Results** under Ind AS for the quarter and half-year ended 30th September, 2017 along with **Limited Review Report of Statutory Auditors of the Company**.

Please find enclosed **Press Release** of our company. We request you to take these documents on your records.

The Board Meeting concluded at 11:45 A.M.

Thanking you,
Yours faithfully,
For **Suven Life Sciences Limited**

A handwritten signature in black ink, appearing to read 'K Hanumantha Rao'.

K Hanumantha Rao
Company Secretary

Suven Life Sciences Limited

Registered Office: 8-2-334 I SDE Serene Chambers I 6th Floor Road No.5 I Avenue 7
Banjara Hills I Hyderabad – 500 034 I Telangana I India I CIN: L24110TG1989PLC009713
Tel: 91 40 2354 1142/ 3311/ 3315 Fax: 91 40 2354 1152 Email: info@suven.com website: www.suven.com



SUVEN LIFE SCIENCES LIMITED


Regd. Off: 8-2-334, SDE Serene Chambers, 6th Floor, Road No.5, Avenue 7, Banjara Hills, Hyderabad - 500 034 CIN: L24110TG1989PLC009713
Tel: 91 40 2354 1142/ 3311/ 3315 Fax: 91 40 2354 1152 email: Investorservices@suvен.com website: www.suven.com

STATEMENT OF UN-AUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTHS ENDED 30th SEPTEMBER 2017

All amounts in Indian Rupees in lakhs

Sl. No.	Particulars	For the Quarter ended			For the Six Months ended		For the Year Ended
		30-Sep-2017	30-Jun-2017	30-Sep-2016	30-Sep-2017	30-Sep-2016	31-Mar-2017
		Un-audited	Un-audited	Un-audited	Un-audited	Un-audited	Audited
1	Revenue from operations						
	(a) Net sales/income from operations (Refer Note 3)	10,409.95	13,744.90	11,554.97	24,154.85	24,877.67	53,916.74
	(b) Other operating income	275.93	357.00	-	632.93	-	531.04
	Total Revenue from operations	10,685.88	14,101.90	11,554.97	24,787.78	24,877.67	54,447.78
2	Other Income	513.23	562.29	675.55	1,075.52	1,125.25	2,109.25
	Total Income (1+2)	11,199.11	14,664.19	12,230.52	25,863.30	26,002.92	56,557.03
3	Expenses						
	(a) Cost of materials consumed	4,218.13	3,683.53	3,406.61	7,901.66	7,392.59	15,480.66
	(b) Purchases of stock-in-trade	-	-	-	-	-	-
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(3,189.36)	(227.17)	(885.88)	(3,416.53)	(922.65)	(295.94)
	(d) Employee benefits expense	1,267.76	1,566.22	1,201.06	2,833.98	2,348.02	5,064.46
	(e) Finance costs	93.58	127.01	123.73	220.59	283.29	566.58
	(f) Depreciation and amortisation expenses	533.99	519.20	455.22	1,053.19	935.80	2,141.31
	(g) Manufacturing expenses	2,101.03	2,190.37	1,909.16	4,291.40	3,650.20	8,157.37
	(h) Research & Development expenses	1,166.13	1,601.19	1,465.36	2,767.32	2,934.37	6,494.09
	(i) Other expenses	622.66	759.06	770.61	1,381.72	1,443.68	3,012.81
	Total expenses	6,813.92	10,219.41	8,445.87	17,033.33	18,065.30	40,621.34
4	Profit before exceptional items and tax (1+2-3)	4,385.19	4,444.78	3,784.65	8,829.97	7,937.62	15,935.69
5	Exceptional Items	-	-	-	-	-	-
6	Profit before tax (4 - 5)	4,385.19	4,444.78	3,784.65	8,829.97	7,937.62	15,935.69
7	Tax Expenses						
	(a) Current tax	592.11	1,132.77	1,295.82	1,724.88	2,182.13	3,275.07
	(b) Deferred tax	618.35	354.94	(166.89)	973.29	(157.84)	313.25
8	Net Profit for the period / year (6-7)	3,174.73	2,957.07	2,655.72	6,131.80	5,913.33	12,347.37
9	Other Comprehensive Income						
9.A	(i) Items that will not be reclassified to profit or loss	(3.72)	(3.73)	(11.31)	(7.45)	(22.61)	(14.90)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	1.29	1.29	-	2.58	-	5.15
9.B	(i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
	Total Other Comprehensive Income	(2.43)	(2.44)	(11.31)	(4.87)	(22.61)	(9.75)
	Total Comprehensive Income (8+9)	3,172.30	2,954.63	2,644.41	6,126.93	5,890.72	12,337.62
10	Paid-up equity share capital (face value of Rs. 1/- each)	1,272.82	1,272.82	1,272.82	1,272.82	1,272.82	1,272.82
11	Earning Per Share (EPS) for continuing operation (face value of Rs.1/- each):						
	a) Basic	2.49	2.32	2.08	4.81	4.63	9.69
	b) Diluted	2.49	2.32	2.08	4.81	4.63	9.69

See accompanying notes to the financial statements




SEGMENT WISE REVENUE, RESULTS TOTAL ASSETS AND LIABILITIES

PARTICULARS	For the Quarter Ended			For the Six Months ended		For the Year Ended
	30-Sep-2017	30-Jun-2017	30-Sep-2016	30-Sep-2017	30-Sep-2016	31-Mar-2017
	Un-audited	Un-audited	Un-audited	Un-audited	Un-audited	Audited
1 SEGMENT REVENUE						
a) Manufacturing (CRAMS)	10,026.47	13,330.76	10,705.18	23,357.23	23,471.57	51,670.07
b) Services (DDDSS)	659.41	771.14	849.79	1,430.55	1,406.10	2,777.71
c) Research & Development	-	-	-	-	-	-
Total	10,685.88	14,101.90	11,554.97	24,787.78	24,877.67	54,447.78
Less: Inter Segment Revenue	-	-	-	-	-	-
Net Sales/Income from Operations	10,685.88	14,101.90	11,554.97	24,787.78	24,877.67	54,447.78
2 SEGMENT RESULTS (Profit/(Loss) before tax and interest)						
a) Manufacturing (CRAMS)	5,312.13	5,782.86	4,696.59	11,094.99	10,293.35	21,634.85
b) Services (DDDSS)	319.36	405.25	503.30	724.61	761.98	1,476.81
c) Research & Development	(1,166.14)	(1,601.18)	(1,465.36)	(2,767.32)	(2,934.37)	(6,494.09)
TOTAL	4,465.35	4,586.93	3,734.53	9,052.28	8,120.96	16,617.57
Less: i) Finance Cost	74.19	87.11	94.99	161.30	208.25	376.38
ii) Other Un-allocable expenditure /(income), net	5.97	55.04	(145.11)	61.01	(24.91)	305.50
Total Profit Before Tax	4,385.19	4,444.78	3,784.65	8,829.97	7,937.62	15,935.69
3 SEGMENT ASSETS :						
a) Manufacturing (CRAMS)	53,711.58	47,190.09	43,759.56	53,711.58	43,759.56	43,886.93
b) Services (DDDSS)	4,077.86	3,511.49	3,598.93	4,077.86	3,598.93	2,828.60
c) Research & Development	2,896.37	2,540.08	2,504.29	2,896.37	2,504.29	2,609.60
d) Un allocated	35,647.25	37,517.52	33,044.05	35,647.25	33,044.05	38,291.82
TOTAL	96,333.06	90,759.18	82,906.83	96,333.06	82,906.83	87,616.95
4 SEGMENT LIABILITIES :						
a) Manufacturing (CRAMS)	9,984.93	8,830.42	8,201.56	9,984.93	8,201.56	8,547.86
b) Services (DDDSS)	574.83	428.06	400.87	574.83	400.87	370.23
c) Research & Development	2,253.38	1,873.25	1,826.23	2,253.38	1,826.23	1,848.18
d) Un allocated	925.47	722.22	684.80	925.47	684.80	687.23
TOTAL	13,738.61	11,853.95	11,113.46	13,738.61	11,113.46	11,453.50

Notes:

- The Company has adopted Indian Accounting Standards ("Ind AS") from April 1 2016 and accordingly these financial results have been prepared in accordance with the recognition and measurement principles laid down in the Ind AS 34 Interim Financial Reporting prescribed under section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and the other accounting principles generally accepted in India. Financial Results for all the periods presented have been prepared in accordance with the recognition and measurement principles of Ind AS 34.
- The above results were reviewed by Audit Committee of the Board and approved by the Board of Directors' at their Meeting held on 11th November, 2017 and the same reviewed by the Statutory Auditors.
- Excise duty on sales was included under Revenue from operations and disclosed separately under expenses upto all reporting periods ending 30-June-2017. Post implementation of Goods and Service Tax (GST) Act w.e.f. 1st July, 2017 the revenue from operations is reported from the quarter ended 30-Sept-2017 are net of GST and hence to that extent not comparable.
- The corresponding previous period figures have been regrouped / reclassified where ever necessary.




For SUVEN LIFE SCIENCES LTD

VENKAT JASTI
 Chairman & CEO
 DIN: 00278028

 Place: Hyderabad
 Date: 11th November, 2017

4) Statement of Asset and Liabilities

Particulars		As at 30-09-2017	As at 31-03-2017
		Unaudited	Audited
		Standalone	Standalone
ASSETS			
1	Non-current assets		
	Property, plant and equipment	30,497.88	30,447.56
	Capital work-in-progress	1,614.11	971.64
	Other intangible assets	118.06	124.83
	Financial assets		
	Investments	7,535.26	6,507.72
	Loans	3.35	3.35
	Other financial assets	582.93	583.93
	Deferred tax assets (net)	-	189.55
	Other non-current assets	-	71.62
	Total non-current assets	40,351.59	38,900.20
2	Current assets		
	Inventories	13,976.79	9,251.14
	Financial assets		
	Investments	26,407.09	30,088.91
	Trade receivables	8,048.54	4,583.32
	Cash and cash equivalents	732.49	414.16
	Bank balance other than cash and cash equivalents	44.05	48.21
	Loans	8.99	7.57
	Other financial assets	0.28	0.71
	Current tax assets (net)	312.46	642.41
	Other current assets	6,450.78	3,680.32
	Total current assets	55,981.47	48,716.75
	TOTAL ASSETS	96,333.06	87,616.95
EQUITY AND LIABILITIES			
1	Equity		
	Equity share capital	1,272.82	1,272.82
	Other equity	78,007.03	71,880.10
	Total equity	79,279.85	73,152.92
2	Liabilities		
	Non-current liabilities		
	Financial liabilities		
	Borrowings	2,130.64	2,593.21
	Provisions	283.50	283.50
	Deferred tax liabilities (net)	781.17	-
	Other non-current liabilities	119.29	133.82
	Total non-current liabilities	3,314.60	3,010.53
	Current liabilities		
	Financial liabilities		
	Borrowings	3,389.78	3,048.52
	Trade payables	6,303.98	3,793.97
	Other financial liabilities	2,365.06	3,257.02
	Other current liabilities	1,129.38	921.08
	Provisions (employee benefit obligations)	521.35	403.85
	Deferred government grants	29.06	29.06
	Total current liabilities	13,738.61	11,453.50
	Total liabilities	17,053.21	14,464.03
	TOTAL EQUITY AND LIABILITIES	96,333.06	87,616.95





Ref No.LR/03/2017-18:

LIMITED REVIEW REPORT

To

The Board of Directors of
SUVEN LIFE SCIENCES LIMITED

We have reviewed the accompanying statement of Unaudited Financial Results ("The Statement") of **SUVEN LIFE SCIENCES LIMITED**, ("the Company") having registered office at SDE Serene Chambers, 6th Floor, Avenue 7, Road No. 5, Banjara Hills, Hyderabad - 500034, Telangana, for the quarter and half year ended 30th September, 2017 attached here with, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Regulations, 2015") read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated 05, July 2016.


The Preparation of the statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standards 34, Interim Financial reporting (IND AS 34) prescribed under section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated 05 July 2016 is the responsibility of the Company's Management and has been approved by the Board of Directors of the Company meeting held on 11 November 2017. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review in accordance with the Standard on Review Engagement ('SRE') 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India ("ICAI"). This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

The Comparative financial results of the Company for the quarter and half year ended 30 September 2016 and for the year ended 31 March 2017 ("together referred to as the comparative financial results"), prepared in accordance with Indian Accounting Standards ("IND AS") included in these financial results have been reviewed/audited by the predecessor auditor who had reviewed/audited the financial results for the relevant period and expressed an unmodified opinion as per the reports dated 24 November 2016 and 13 May 2017 respectively.

Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with applicable Ind AS prescribed under section 133 of the Companies Act, 2013, read with relevant rules issued there under and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of SEBI Regulations 2015, read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 05, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **TUKARAM & CO.**,
Chartered Accountants
(Firm Registration No.004436S)


(**RAJENDER REDDY K**)
P A R T N E R
M.No. 231834



Place: Hyderabad
Date: 11/11/2017

News Release

Suven Income at INR 2586 Mn; PAT at INR 613 Mn for the half year ended September 2017

HYDERABAD, INDIA (11th November, 2017) – Suven Life Sciences Limited, a biopharmaceutical company specializing in drug discovery and developmental activities in Central Nervous System disorders, today announced its Un-audited financial results for the quarter ended 30th September 2017. The un-audited financial results were reviewed by the audit committee and approved by the Board of Directors in their meeting held on 11th November, 2017 at Hyderabad.

Financial Highlights for the Half year ended September' 2017:

Growth in revenue	INR 2586 Mn vs INR 2600 Mn - down by 0.54%
Growth in PAT	INR 613 Mn vs. INR 589 Mn - up by 4.01%
Growth in EBIDTA	INR 1010 Mn vs. INR 913 Mn - up by 10.56%

Financial Highlights for the 2nd Quarter ended September' 2017 (QoQ):

Growth in revenue	INR 1120 Mn vs INR 1466 Mn - down by 23.63%
Growth in PAT	INR 317 Mn vs. INR 295 Mn - up by 7.37%
Growth in EBIDTA	INR 501 Mn vs. INR 509 Mn - down by 1.54%

Suven's major thrust on innovative R&D in Drug Discovery continues with a spending of INR 277 Mn (10.70% on income) for the half year ended September 2017.

For more information on Suven please visit our Web site at <http://www.suven.com>

Risk Statement:

Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained, if any, in this news release may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive

Suven Life Sciences Limited